CDK5R1 and central nervous system cancer: Accordingly, in breast cancer, prostate cancer, lung cancer, colorectal cancer, melanoma, pituitary adenoma, leukemia, hepatocellular carcinoma (HCC), gliomas and MTC, both CDK5 and p35 levels are increased (Table 1).